Q1 Earnings Estimate for RNAC Issued By HC Wainwright

Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Cartesian Therapeutics in a note issued to investors on Monday, May 19th. HC Wainwright analyst M. Kapoor forecasts that the company will post earnings of ($0.80) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $40.00 target price on the stock. The consensus estimate for Cartesian Therapeutics' current full-year earnings is $4.56 per share. HC Wainwright also issued estimates for Cartesian Therapeutics' Q2 2026 earnings at ($0.94) EPS, Q3 2026 earnings at ($1.10) EPS, Q4 2026 earnings at ($1.22) EPS and FY2026 earnings at ($4.06) EPS.

Separately, Needham & Company LLC decreased their price objective on Cartesian Therapeutics from $41.00 to $40.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $43.00.

Cartesian Therapeutics Stock Up 0.1%

Shares of RNAC traded up $0.01 during trading hours on Tuesday, hitting $9.16. The company had a trading volume of 53,651 shares, compared to its average volume of 115,218. The firm has a market cap of $237.74 million, a P/E ratio of -0.17 and a beta of 0.51. The stock's 50 day moving average price is $11.69 and its 200 day moving average price is $16.31. Cartesian Therapeutics has a 52-week low of $8.85 and a 52-week high of $41.87.

Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.07). The company had revenue of $1.10 million during the quarter, compared to the consensus estimate of $0.69 million.

Hedge Funds Weigh In On Cartesian Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. MPM Bioimpact LLC lifted its holdings in shares of Cartesian Therapeutics by 9.7% during the 1st quarter. MPM Bioimpact LLC now owns 790,779 shares of the company's stock valued at $10,422,000 after buying an additional 69,640 shares during the period. Erste Asset Management GmbH increased its stake in shares of Cartesian Therapeutics by 49.8% in the 1st quarter. Erste Asset Management GmbH now owns 260,011 shares of the company's stock worth $3,432,000 after purchasing an additional 86,445 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Cartesian Therapeutics by 63.0% in the 4th quarter. Geode Capital Management LLC now owns 221,257 shares of the company's stock worth $3,963,000 after purchasing an additional 85,557 shares in the last quarter. 683 Capital Management LLC increased its stake in shares of Cartesian Therapeutics by 20.0% in the 1st quarter. 683 Capital Management LLC now owns 150,000 shares of the company's stock worth $1,977,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Northern Trust Corp increased its stake in shares of Cartesian Therapeutics by 50.6% in the 4th quarter. Northern Trust Corp now owns 95,030 shares of the company's stock worth $1,702,000 after purchasing an additional 31,915 shares in the last quarter. 86.95% of the stock is owned by institutional investors.

About Cartesian Therapeutics

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.